Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study
A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a sign...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2024-12-01
|
| Series: | West Kazakhstan Medical Journal |
| Subjects: | |
| Online Access: | https://knepublishing.com/index.php/wkmj/article/view/17780 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase.
|
|---|---|
| ISSN: | 2707-6180 2707-6199 |